1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

  • December 2017
  • 39 pages
  • ID: 5257629
In this report:
IN THE ##MM, THE NUMBER OF DIAGNOSED INCIDENT CASES OF ALL CANCER WILL GROW BY ##.##% OVER THE FORECAST PERIOD, AT AN ANNUAL GROWTH RATE (AGR) OF ##.##%, FROM ##,##,## CASES IN 2016 TO ##,##,## CASES BY 2026.
OF THE ##MM, THE US IS EXPECTED TO HAVE THE HIGHEST NUMBER OF DIAGNOSED INCIDENT CASES, INCREASING FROM ##,##,## IN 2016 TO ##,##,## IN 2026.
THIS IS EXPECTED TO GROW TO ##,## CASES OF BONE METASTASIS FOR INCIDENT CASES DIAGNOSED IN 2026 AT AN AGR OF ##.##%.

Summary

Table of Contents

Search Inside

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

Brief

Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation in any part of the body that may spread beyond the cells' normal boundaries (WHO, 2017). Worldwide, it is estimated that around 14 million additional cases of cancer are diagnosed each year, and 30 - 50.0 percent of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017). The etiology of cancer varies with each type; however, the most common risk factors contain tobacco use, lack of physical exercise, unhealthy diet, and old age (WHO, 2017).

In 2016, there were more than 900,000 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with more than 75.0 percent of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remainder of about 24.0 percent casesreceived chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were more than 800,000 cases of chemotherapy-induced anemia and almost 750,000 cases of chemotherapy-induced nausea and vomiting in the 7MM.

In 2016, Spain (ES) had the more considerable age-standardized diagnosed incidence of all cancer in men at more than 570 cases per 100,000. Germany (DE) had the lowest age-standardized diagnosed incidence of all cancer in men at around 428 cases per 100,000.The U.S. had an age-standardized diagnosed incidence of all cancer of about 435 cases per 100,000 in 2016. As far as womenare concerned, in 2016, the U.S. had the more significant age-standardized rate of over 400 cases per 100,000, while Japan (JP) had the lowest rate at around 325cases per 100,000. The United Kingdom (UK) had the more important age-standardized rate of around 400 cases per 100,000 out of the five European countries (5EU: France (FR), Germany (DE), Italy (IT), Spain (ES), and UK).

The analysis "EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026", offers an overview of the overall and historical trends for all cancer in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all cancer broken down by age (beginning at 18 years and ending at 80 years and older) and sex. It also offers the proportion of all cancer cases treated with chemotherapy and the number of those cases that develop a chemotherapy-induced condition.

Furthermore, this business report offers the number of diagnosed incident cases of prostate (men ages 35 years and older), breast (women ages 20 years and older), and lung cancer (men and women ages 20 years and older), and the proportion of those that metastasize to bone. Finally, the market research also offers a forecast of the 5-year diagnosed prevalent cases of all cancer in men and women combined (ages 18 years and older).

Overview

- The Supportive Care in Oncology EpiCast Report offers an overview of the risk factors and overall trends of supportive care in oncology in the seven main markets (7MM: US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)).

- This industry report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; 5-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.

- The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The Supportive Care in Oncology EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall oncology and chemotherapy treatment market.

- Quantify patient populations in the overall oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.

- Understand magnitude of chemotherapy induced conditions.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

  • $ 6995
  • Industry report
  • July 2018
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast CancerSummaryBreast cancer remains a major global healthcare ...

Digital Landscape: Breast Cancer

Digital Landscape: Breast Cancer

  • $ 6000
  • Industry report
  • September 2018
  • by GlobalData

Digital Landscape: Breast CancerSummary"Digital Landscape: Breast Cancer", analyzes digital activities undertaken by pharma in support of therapies for Breast Cancer.- The report includes digital activities ...

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • Industry report
  • July 2018
  • by GBI Research

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the MarketSummaryMany countries are facing the challenge of an aging ...

Global Alpha Emitters Market $ 4250 August 2018


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on